Please ensure Javascript is enabled for purposes of website accessibility

5 Reasons Canada Is Facing a Marijuana Shortage

By Sean Williams – Nov 18, 2018 at 8:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It took just hours for some dispensaries to run out of cannabis.

The marijuana industry has delivered one milestone after another in 2018.

The highlight, of course, was the legalization of recreational cannabis in Canada on Oct. 17, 2018, which ended nine decades of adult-use prohibition. However, we also witnessed two more U.S. states legalize medical pot, which went along with Michigan becoming the 10th state to OK recreational weed use. Add in pot stock uplistings, the first cannabis-derived drug being approved in the U.S., and Tilray becoming the first pot stock to IPO on a reputable U.S. exchange, and you have the makings of a groundbreaking year.

A Canadian flag with a red cannabis leaf and a sold out stamp covering the flag.

Image source: Getty Images.

Canada is facing serious cannabis supply concerns

Yet despite all of this, the industry has still had its hiccups. In particular, Canada has run into major supply shortages since legalization. Following more than 12,500 in-store transactions and 30,000 online orders in Quebec on the first day of legalization, SDQC (the branch in charge of managing weed sales in the province) had to remove numerous products from its online store because they were sold out. One location in Winnipeg, Manitoba, had to close its doors just hours after opening because it ran out of product.

Why are Canadian dispensaries and online stores struggling with supply shortages, you ask? Well, don't look to any one specific reason for the answer. Instead, blame it on a combination of five factors.

1. Growers had to be certain about legalization before they ramped up capacity

To begin with, you can point the finger at the Canadian government for waffling on legalization for as long as it did. As long as Canada's Parliament was debating the Cannabis Act, there was no guarantee that it would be approved. It was only in December 2017, when nearly all provinces committed to a two-year tax-sharing agreement with the federal government, that it became clear to growers the bill had a very good chance of passing and becoming a law.

With only medical cannabis being legalized prior to the Cannabis Act, most growers had very little ongoing in the way of capacity expansion. For example, Aurora Cannabis (ACB -1.64%) was only on track to produce a little over 100,000 kilograms annually when the year began. Then it (and other pot stocks) began spending liberally. Two major acquisitions, a huge partnership in Denmark, and multiple organic projects later, Aurora Cannabis could be on pace to yield 700,000 kilograms per year by 2021.

However, it's going to take time for Aurora Cannabis and its peers to up their production. Most marijuana growers are probably a good 12 to 36 months away from hitting their pie-in-the-sky annual production targets. That means reduced output in the interim, and the likely need for investors to reduce their lofty expectations.

A tipped over jar filled with dried cannabis that's lying atop a small pile of cash bills.

Image source: Getty Images.

2. Access to capital has been challenging for growers

To build on the previous point, another problem in boosting production capacity has been financing. Even though cannabis is now legal in Canada, access to capital still remains dicey, at best. With banks not wanting to face criminal and/or financial penalties, they've mostly chosen to steer clear of the pot industry.

This has left publicly traded pot stocks like Aurora to turn to their most reliable source of funding: bought-deal offerings. A bought-deal offering involves the sale of common stock, convertible debentures, stock options, and/or warrants in order to raise capital. While dilutive in the short and potentially long term, these capital raises do the trick.

Unfortunately, financing for nonpublic growers hasn't been so easy to come by. The lack of financing options has constrained growing capacity for smaller operators, hurting Canada's supply.

3. Cultivation licensing delays have slowed production

The finger of blame can also be pointed squarely at Health Canada, which is in charge of regulating the cannabis industry. More specifically, Health Canada has a responsibility to review and approve cultivation license applications. As reported by Marijuana Business Daily in May, the regulatory agency had a backlog of more than 500 cultivation applications to approve or deny. This figure may have since grown, with more than double the number of cultivation licenses received during the first four months of 2018, compared with the first four months of 2017.

Through Oct. 26, per Health Canada's website, just 132 cultivation licenses had been issued, with most in Ontario (69), British Columbia (30), and Quebec (12). It could take many more months, if not years, for Health Canada to catch up on all of these cultivation license applications. 

A large marijuana sign outside of a dispensary

Image source: Getty Images.

4. Sales permit delays can be even longer

Just to complicate things even more, Health Canada is also in charge of issuing sales permits. That's right, in addition to cannabis growers needing the go-ahead from regulators to legally plant and harvest marijuana, they also need a permit from Health Canada to sell it. The wait for a sales permit can be just as long, if not longer, than the cultivation license.

Once again pulling from data supplied by Marijuana Business Daily back in May, the average wait to obtain a sales permit was 341 days. That's more than 11 months just to be given the OK to sell already harvested cannabis. No grower has been able to obtain a sales license quicker than CannTrust Holdings, which accomplished the feat in "only" 129 days (just over four months). As with cultivation license delays, these sales permit delays could hinder the amount of product that makes it onto dispensary shelves.

5. Initial euphoria usually drains supply

Lastly, consumers deserve some of the blame.

Although there's little precedence to recreational legalization around the world, we've witnessed similar shortages in Nevada following its legalization in July 2017, and in Colorado in January 2014. These shortages are tied to the initial euphoria consumers felt once cannabis was legalized. Although this euphoria only tends to last a few months, it has a draining near-term effect on supply, which has been geared to meet "normal" demand. This euphoria is probably going to lead to supply concerns for months to come in Canada.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends CannTrust Holdings Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
$1.20 (-1.64%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.